<DOC>
	<DOCNO>NCT00004800</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare efficacy 2 acellular pertussis vaccine vs. whole-cell pertussis vaccine vs. placebo infant live Italy . II . Compare relative protection acellular vaccine vs. whole-cell vaccine vs. laboratory-confirmed pertussis . III . Assess relative efficacy acellular vaccine respect one another . IV . Assess immunogenicity acellular vs. whole-cell vaccine study population . V. Compare frequency adverse event vaccine . VI . Compare frequency adverse event attributable pertussis component 3 vaccine . VII . Assess alternative laboratory diagnostic technique pertussis estimate vaccine efficacy , i.e. , mucosal immune response , DNA probe , antibody response component organism . VIII . Assess relative efficacy estimate vaccine , use clinical criterion compare relative incidence rate vaccine group .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Placebo-Controlled Study Acellular Whole-Cell Pertussis Vaccines</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution randomly assign 1 3 vaccine placebo vaccine 3:3:3:1 ratio . One group receive diphtheria-tetanus-pertussis ( DPT ) vaccine contain filamentous hemagglutinin ( FHA ) , Pt-9K/129G , 69 kDA outer membrane protein ( OMP ) . A second group receive DPT contain FHA OMP . The third group receive DPT contain whole-cell pertussis . The control group receive diphtheria-tetanus ( DT ) vaccine . All vaccine administer intramuscular deep subcutaneous injection 6-12 , 13-20 , 21-28 week age . The first vaccine give week 12 hepatitis B immune globulin give birth . All patient receive DT booster 11 month , follow every 4 week approximately 20 month .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Population Characteristics Newborns enrol first vaccine clinic visit Weight first vaccination least third percentile , i.e . : Girls : 3.2 3.8 kg Boys : 3.4 4.0 kg No previous illness compatible pertussis Prior/Concurrent Therapy No prior pertussis vaccination Patient Characteristics Age : Over 6 week 12 week Renal : No renal failure Other : No prior prolong immunosuppressive therapy No prior systemic corticosteroid , unless duration le 14 day least 48 hour since last dose No major congenital abnormality No failure thrive No known possible immune system deficit , e.g . : HIVinfected mother Autoimmune anemia Lymphoma Other erythropoietic disease No perinatal central nervous system disease damage No history convulsion Mother Italianspeaking accessible telephone Planned residence clinic district least 1 year</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>February 1998</verification_date>
	<keyword>bacterial infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>pertussis</keyword>
	<keyword>rare disease</keyword>
</DOC>